Literature DB >> 6859087

Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.

R G Ungerer, D P Tashkin, D Furst, P J Clements, H Gong, M Bein, J W Smith, N Roberts, W Cabeen.   

Abstract

Forty-nine patients with progressive systemic sclerosis who had undergone extensive studies including pulmonary artery catheterization as part of an ongoing prospective study of the natural course of progressive systemic sclerosis were evaluated. The overall prevalence of pulmonary arterial hypertension in this population of patients with progressive systemic sclerosis was 33 percent, and among 10 subjects with the CREST syndrome the prevalence of pulmonary hypertension was 50 percent. The relation between pulmonary arterial hypertension documented at catheterization and abnormal results of noninvasive studies suggesting pulmonary hypertension, including physical examination, chest x-ray, electrocardiography, echocardiography, single-breath diffusing capacity, and vital capacity, was studied. Diffusing capacity was significantly lower in those patients with definite pulmonary hypertension (mean pulmonary artery pressure of 22 mg Hg or more) compared with those with a normal mean pulmonary artery pressure, and a diffusing capacity below 43 percent of predicted showed the greatest sensitivity (67 percent) of any single diagnostic test in detecting definite pulmonary hypertension. Chest x-ray suggesting pulmonary hypertension was the least sensitive of the tests evaluated, but showed the greatest specificity (100 percent) in identifying patients with pulmonary hypertension. A classification matrix based on discriminant function analysis utilizing the combination of diffusing capacity below 43 percent of predicted and chest x-ray and electrocardiographic findings correctly identified 75 percent of patients with definite pulmonary hypertension and 97 percent of patients with a normal pulmonary artery pressure, but failed to identify correctly patients with mild pulmonary hypertension (mean pulmonary artery pressure of 20 mm Hg). These findings indicate that specific noninvasive studies are helpful in assessing the likelihood of normal or definitely elevated pulmonary artery pressures in patients with progressive systemic sclerosis, but patients with mild pulmonary hypertension are not likely to be identified by these noninvasive studies.

Entities:  

Mesh:

Year:  1983        PMID: 6859087     DOI: 10.1016/0002-9343(83)91169-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

Review 1.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 2.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

3.  Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.592

4.  Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis.

Authors:  Walter Serra; Alfredo Chetta; Daniele Santilli; Flavio Mozzani; Pier Paolo Dall'Aglio; Dario Olivieri; Maria Alberta Cattabiani; Diego Ardissino; Tiziano Gherli
Journal:  Cardiovasc Ultrasound       Date:  2010-07-05       Impact factor: 2.062

Review 5.  Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.

Authors:  Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 6.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

7.  Left ventricular wall thickness and disease duration in systemic sclerosis.

Authors:  I Hegedüs; L Czirják
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

Review 8.  Imaging lung disease in systemic sclerosis.

Authors:  Diane Strollo; Jonathan Goldin
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

9.  L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance.

Authors:  S V Baudouin; P Bath; J F Martin; R Du Bois; T W Evans
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

10.  Severe Pulmonary Hypertension in Primary Sjögren's Syndrome.

Authors:  Ji-An Hwang; Tae-Hyun Yang; Ji-Young Lee; Dong-Wan Koo; In Suk Choi; Sun-Young Cho; Min-Sung Kim
Journal:  Korean Circ J       Date:  2013-07-31       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.